Get the Stockscreener App
9.55
0.10%
0.01
After Hours:
9.60
0.05
+0.52%
Amneal Pharmaceuticals Inc stock is traded at $9.55, with a volume of 1.62M.
It is up +0.10% in the last 24 hours and up +19.97% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$9.54
Open:
$9.5
24h Volume:
1.62M
Relative Volume:
1.00
Market Cap:
$3.00B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-14.03
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+0.00%
1M Performance:
+19.97%
6M Performance:
+8.03%
1Y Performance:
+12.49%
1-Day Range:
$9.32
$9.61
1-Week Range:
$9.32
$9.76
52-Week Range:
$6.685
$9.79
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
9.55 | 3.01B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
153.20 | 67.75B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.29 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.84 | 43.70B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.48 | 21.51B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
380.47 | 18.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Published on: 2025-09-04 23:43:12 - Newser
Can technical indicators confirm Amneal Pharmaceuticals Inc.’s reversalMarket Movement Recap & Expert Curated Trade Setup Alerts - Newser
Amneal Pharmaceuticals Receives FDA Approval for Antipsychotic Medicine - AInvest
Amneal receives U.S. FDA approval for risperidone extended-release injectable suspension - MarketScreener
Amneal gets FDA nod for generic version of Risperdal Consta - Seeking Alpha
FDA approves Amneal’s generic risperidone for schizophrenia treatment - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Risperidone Extended-Release Injectable Suspension - Quiver Quantitative
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension - GlobeNewswire
Amneal Pharmaceuticals Receives FDA Approval for Risperidone Extended-Release Injectable Suspension, Expanding Complex Injectables Portfolio - AInvest
$194M Market Opportunity: Amneal Secures Exclusive FDA Approval for Complex Injectable Schizophrenia Drug - Stock Titan
Has Amneal Pharmaceuticals Inc. formed a bullish divergence2025 Trade Ideas & Consistent Growth Equity Picks - Newser
Detecting price anomalies in Amneal Pharmaceuticals Inc. with AIQuarterly Market Review & Fast Gain Stock Trading Tips - Newser
Will Amneal Pharmaceuticals Inc. continue its uptrendVolume Spike & Daily Volume Surge Signals - Newser
Can Amneal Pharmaceuticals Inc. expand into new marketsWeekly Investment Summary & Capital Protection Trading Alerts - khodrobank.com
Top chart patterns to watch in Amneal Pharmaceuticals Inc.Rate Hike & Breakout Confirmation Alerts - Newser
Can machine learning forecast Amneal Pharmaceuticals Inc. recoveryMarket Activity Summary & Breakout Confirmation Alerts - Newser
Amneal Pharmaceuticals Inc. stock trend forecast2025 Top Gainers & Reliable Volume Spike Alerts - Newser
Is it too late to sell Amneal Pharmaceuticals Inc.2025 Winners & Losers & Daily Growth Stock Investment Tips - Newser
How hedge fund analytics apply to Amneal Pharmaceuticals Inc. stockWeekly Trading Summary & AI Enhanced Trading Signals - Newser
What are the risks of holding Amneal Pharmaceuticals Inc.2025 Geopolitical Influence & Advanced Technical Signal Analysis - khodrobank.com
Is Amneal Pharmaceuticals Inc.’s ROE strong enoughQuarterly Trade Review & Capital Efficiency Focused Strategies - khodrobank.com
Amneal Pharmaceuticals Inc. stock daily chart insightsQuarterly Earnings Summary & Fast Momentum Entry Tips - Newser
What makes Amneal Pharmaceuticals Inc. stock attractive todayPortfolio Return Report & AI Powered Buy and Sell Recommendations - khodrobank.com
Regression analysis insights on Amneal Pharmaceuticals Inc. performanceJuly 2025 Closing Moves & Weekly Chart Analysis and Guides - Newser
Does Amneal Pharmaceuticals Inc. qualify in momentum factor screeningPortfolio Risk Report & Real-Time Volume Spike Alerts - Newser
Published on: 2025-09-03 02:26:05 - Newser
Should you wait for a breakout in Amneal Pharmaceuticals Inc.Quarterly Risk Review & Free Real-Time Market Sentiment Alerts - Newser
Comparing Amneal Pharmaceuticals Inc. in custom built stock radarsGlobal Markets & Long-Term Safe Investment Plans - Newser
Is Amneal Pharmaceuticals Inc. building a consolidation basePortfolio Return Report & High Accuracy Swing Entry Alerts - Newser
Is Amneal Pharmaceuticals Inc. forming a bullish divergenceTrade Exit Report & Long-Term Growth Plans - khodrobank.com
Tools to monitor Amneal Pharmaceuticals Inc. recovery probability2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - Newser
Published on: 2025-09-02 10:39:09 - Newser
Is Amneal Pharmaceuticals Inc. stock showing strong momentum2025 Technical Overview & Real-Time Buy Zone Alerts - khodrobank.com
Analyzing net buyer seller activity in Amneal Pharmaceuticals Inc.Exit Point & Reliable Price Breakout Alerts - Newser
Is Amneal Pharmaceuticals Inc. stock undervalued right nowInsider Buying & Risk Adjusted Buy/Sell Alerts - khodrobank.com
Why Amneal Pharmaceuticals Inc. is moving todayRisk Management & Verified Technical Signals - Newser
Is Amneal Pharmaceuticals Inc. being accumulated by smart moneyPrice Action & AI Driven Stock Reports - khodrobank.com
Using data models to predict Amneal Pharmaceuticals Inc. stock movementTake Profit & Intraday High Probability Setup Alerts - Newser
Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a Bet - sharewise.com
Fundamentals Check: Is Amneal Pharmaceuticals Inc. a strong growth stockJuly 2025 Fed Impact & Reliable Volume Spike Trade Alerts - khodrobank.com
How to forecast Amneal Pharmaceuticals Inc. trends using time seriesEarnings Beat & Stock Portfolio Risk Control - Newser
Amneal Pharmaceuticals Inc. Approaches Support With Recovery in Sight getLinesFromResByArray error: size == 0 - 강소기업뉴스
Key resistance and support levels for Amneal Pharmaceuticals Inc.Dollar Strength & High Conviction Investment Ideas - Newser
Amneal Pharmaceuticals Inc. Stock Recovery Path — Analyst Breakdown2025 Market Outlook & Risk Controlled Daily Plans - beatles.ru
Can a trend reversal in Amneal Pharmaceuticals Inc. lead to recoveryRate Cut & Long-Term Capital Growth Strategies - Newser
Using data tools to time your Amneal Pharmaceuticals Inc. exitJuly 2025 Trends & Consistent Profit Trade Alerts - Newser
Building trade automation scripts for Amneal Pharmaceuticals Inc.Portfolio Update Summary & High Conviction Buy Zone Alerts - Newser
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.60%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):